Vertex Pharmaceuticals Statistics

Total Valuation

Vertex Pharmaceuticals has a market cap or net worth of EUR 98.22 billion. The enterprise value is 89.14 billion.

Market Cap	98.22B
Enterprise Value	89.14B

Important Dates

The next estimated earnings date is Thursday, February 6, 2025.

Earnings Date	Feb 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.91%
Shares Change (QoQ)	+1.12%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	256.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	7.99
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.63, with an EV/FCF ratio of -89.91.

EV / Earnings	-207.21
EV / Sales	8.74
EV / EBITDA	20.63
EV / EBIT	21.91
EV / FCF	-89.91

Financial Position

The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.11.

Current Ratio	2.47
Quick Ratio	2.08
Debt / Equity	0.11
Debt / EBITDA	0.39
Debt / FCF	-1.60
Interest Coverage	110.38

Financial Efficiency

Return on equity (ROE) is -2.99% and return on invested capital (ROIC) is 15.29%.

Return on Equity (ROE)	-2.99%
Return on Assets (ROA)	12.05%
Return on Capital (ROIC)	15.29%
Revenue Per Employee	1.76M
Profits Per Employee	-79,665
Employee Count	5,400
Asset Turnover	0.48
Inventory Turnover	5.58

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +2.99% in the last 52 weeks. The beta is 0.46, so Vertex Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.46
52-Week Price Change	+2.99%
50-Day Moving Average	441.71
200-Day Moving Average	424.08
Relative Strength Index (RSI)	24.25
Average Volume (20 Days)	169

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.68

Income Statement

In the last 12 months, Vertex Pharmaceuticals had revenue of EUR 9.53 billion and -430.19 million in losses. Loss per share was -1.67.

Revenue	9.53B
Gross Profit	5.11B
Operating Income	3.80B
Pretax Income	232.76M
Net Income	-430.19M
EBITDA	3.99B
EBIT	3.80B
Loss Per Share	-1.67

Full Income Statement

Balance Sheet

The company has 5.85 billion in cash and 1.59 billion in debt, giving a net cash position of 8.48 billion.

Cash & Cash Equivalents	5.85B
Total Debt	1.59B
Net Cash	8.48B
Net Cash Per Share	n/a
Equity (Book Value)	14.01B
Book Value Per Share	54.38
Working Capital	5.23B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -755.48 million and capital expenditures -235.99 million, giving a free cash flow of -991.46 million.

Operating Cash Flow	-755.48M
Capital Expenditures	-235.99M
Free Cash Flow	-991.46M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 53.59%, with operating and profit margins of 39.89% and -4.52%.

Gross Margin	53.59%
Operating Margin	39.89%
Pretax Margin	2.44%
Profit Margin	-4.52%
EBITDA Margin	41.85%
EBIT Margin	39.89%
FCF Margin	n/a

Dividends & Yields

Vertex Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.91%
Shareholder Yield	0.91%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on August 24, 2000. It was a forward split with a ratio of 2.

Last Split Date	Aug 24, 2000
Split Type	Forward
Split Ratio	2

Scores

Vertex Pharmaceuticals has an Altman Z-Score of 11.97.

Altman Z-Score	11.97
Piotroski F-Score	n/a